The 2-oxindole chemotype and patent activity inspired by the SU5416 franchise

Expert Opinion on Therapeutic Patents

Volumn 13, Issue 6, 2003, Pages 737-749

  Connell, Richard D ^a  

^a PFIZER INC   (United States)

Author keywords

Indolones; Kinase inhibitors; Oxindole; Semaxinib; SU11248; SU5416; SU6668

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; AROMATASE INHIBITOR; BENZENE DERIVATIVE; CAMPTOTHECIN DERIVATIVE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLODEXTRIN DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; ESTRAMUSTINE PHOSPHATE; EXEMESTANE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; GEFITINIB; HUMAN ALBUMIN; HYDRAZINE DERIVATIVE; LOMETREXOL; OXINDOLE; PEPTIDE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; SEMAXANIB; SOMATOMEDIN C RECEPTOR; SU 4312; SU 4932; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2;

ANTINEOPLASTIC ACTIVITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MARKETING; DRUG MECHANISM; DRUG POTENCY; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; ELECTROPORATION; ENDOMETRIOSIS; ENZYME INHIBITION; HUMAN; PATENT; REVIEW; STRUCTURE ACTIVITY RELATION; UTERUS MYOMA;

EID: 0037971531     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.13.6.737     Document Type: Review

References (14)

1. AL-OBEIDI FA, LAM KS: Development of inhibitors for protein tyrosine kinases. Oncogene (2000) 19:5690-5701.
2. LEVITZKI A: Protein tyrosine kinase inhibitors as therapeutic agents. Bioorg. Chem. Biol. Signal Transduction (2001) 211:1-15.
3. DUMAS J: Protein kinase inhibitors: emerging pharmacophores 1997-2000. Exp. Opin. Ther. Patents (2001) 11(3):405-429.
4. NO AUTHORS LISTED: Sugen acquisition would add three anticancer agents to P&U pipeline. Scrip (17 June 1999).
5. NO AUTHORS LISTED: Pharmacia drops lead angiogenesis product. Scrip (12 February 2002).
6. NO AUTHORS LISTED: Pharmacia's SU5416 not effective. Exp. Rev. Anticancer Ther. (2002) 2(1):5-8.
7. SUN L, TRAN N, TANGF, APP H, HIRTH P et al.: Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J. Med. Chem. (1998) 41(14):2588-2603.
8. SUN L, TRAN N, LIANG C,TANGF, RICE A et al.: Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF and PDGF receptor tyrosine kinases. J. Med Chem. (1999) 42(25):5120.
9. ZHAO YP, YANG CY, HAZNEDAR J, ANTONIAN L: Simultaneous determination of SU5416 and its phase I and phase II metabolites in rat and dog plasma by LC/MS/MS. J. Pharm. Biomed. Anal. (2001) 25:821-832.
10. MENDEL DB, LAIRD AD, XIN XH, LOUIE SG, CHRISTENSEN JG et al.: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. (2003) 9:327-337.
11. MANLEY PW, MARTINY-BARON G, SCHLAEPPI JM, WOOD JM: Therapies directed at vascular endothelial growth factor. Exp. Opin. Investig. Drugs (2002) 11:1715-1736.
12. LACKEY K, CORY M, DAVIS R et al.: The discovery of potent cRaf1 kinase inhibitors. Bioorg. Med. Chem. Lett. (2000) 10(3):223-226.
13. BRAMSON HN, CORONA J, DAVIS ST et al.: Oxindole-based inhibitors of cyclin-dependent kinase 2 (Cdk2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis. J. Med. Chem. (2001) 44(25):4339-4358.
14. MESTERS RM, PADRO T, BIEKER R, STEINS M, KREUTER M et al.: Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood (2001) 98:241-243.